OBJECTIVE: To evaluate @entity1037 as a @entity2686 abortive agent in an open-label trial. BACKGROUND: @entity2686 is the most @entity158 known. There are very few recognized abortive therapies for @entity2686 and fewer for @entity1 who have contraindications to vasoconstrictive drugs. METHODS: @entity1037 was given as an abortive agent to five @entity1 with @entity2686 in an open-label trial. The initial @entity1037 dose was 5 mg, and the dose was increased to 10 mg if there was no @entity158 relief. The dosage was decreased to 2.5 mg if the 5-mg dose was effective but caused adverse effects. To be included in the study, each @entity1 had to treat at least two attacks with either an effective dose or the highest tolerated dose. RESULTS: Five @entity1 completed the investigation (four @entity1 , one @entity1 ; four with chronic cluster, one with episodic cluster). @entity1037 reduced @entity158 by at least 80% in four of five @entity1 , and two @entity1 became @entity10 -free after taking the drug. @entity1037 typically alleviated @entity158 within 20 minutes after oral dosing and treatment response was consistent across multiple treated attacks. The only adverse event was @entity25 . CONCLUSIONS: @entity1037 appears to be a good abortive agent for @entity2686 . It @entity158 quickly and has a consistent response across multiple treated attacks. It appears to work in both episodic and chronic @entity2686 .

@entity1037 as an abortive agent for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'woman', 'patient', 'men'] @entity2686 :: ('MESH:D003027', 'Disease') :: ['cluster headache', 'Cluster headache'] @entity158 :: ('MESH:D010146', 'Disease') :: ['painful headache syndrome', 'alleviates pain', 'pain', 'cluster pain'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['Olanzapine', 'olanzapine'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleepiness']
@entity2686 :: (MESH:D003027,Disease) :: ['cluster headache']
